| scholarly article | Q13442814 |
| P50 | author | V. Craig Jordan | Q7906022 |
| P2093 | author name string | Philipp Y Maximov | |
| Fadeke Agboke | |||
| Russell McDaniel | |||
| P2860 | cites work | A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 | Q24564911 |
| Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels | Q24672877 | ||
| The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice | Q26830744 | ||
| The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation | Q28137833 | ||
| Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial | Q28244429 | ||
| Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women | Q28251695 | ||
| Lasofoxifene in postmenopausal women with osteoporosis | Q28274186 | ||
| Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial | Q28277066 | ||
| Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study | Q28281843 | ||
| Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study | Q28283241 | ||
| Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer | Q28284429 | ||
| Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial | Q28289262 | ||
| The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women | Q29396434 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q29619251 | ||
| Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer | Q33642104 | ||
| Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer | Q34110074 | ||
| Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats | Q34118797 | ||
| A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? | Q34161156 | ||
| In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo | Q34174902 | ||
| Tamoxifen: a most unlikely pioneering medicine | Q34180688 | ||
| The estrogen receptor: a model for molecular medicine. | Q34204428 | ||
| Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture | Q34219324 | ||
| Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials | Q35186747 | ||
| Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships | Q36096945 | ||
| A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization | Q36460672 | ||
| A receptor molecule for estrogens: studies using a cell-free system | Q36463856 | ||
| A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer | Q36468027 | ||
| Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial | Q36680024 | ||
| The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole | Q39524591 | ||
| Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations | Q39554511 | ||
| Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor | Q39932233 | ||
| Anti-oestrogen action in experimental breast cancer. | Q40257117 | ||
| What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective | Q40503243 | ||
| Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. | Q40727923 | ||
| Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens | Q40805785 | ||
| Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer | Q41521294 | ||
| Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers | Q42189678 | ||
| Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. | Q42258728 | ||
| Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats | Q42288352 | ||
| Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats | Q42289106 | ||
| The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. | Q42289338 | ||
| Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. | Q42836293 | ||
| Selective accumulation of tritium-labelled hexoestrol by the reproductive organs of immature female goats and sheep | Q42950233 | ||
| Effects of an antioestrogen on the corpus luteum of rabbits and rats | Q43431467 | ||
| Role of Oestrogen in Spontaneous Ovulation demonstrated by Use of an Antagonist of Oestrogen, ICI 46,474 | Q43627386 | ||
| Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators | Q43988923 | ||
| A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity | Q44004732 | ||
| First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial | Q44146948 | ||
| Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene | Q45168977 | ||
| A new derivative of triphenylethylene: effect on implantation and mode of action in rats. | Q51218880 | ||
| Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. | Q51614708 | ||
| Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. | Q54347791 | ||
| Role of Estrogens in Spontaneous Ovulation: Evidence for Positive Feedback in Hamsters | Q54517023 | ||
| Metabolism of tamoxifen and its uterotrophic activity. | Q54519312 | ||
| Contrasting Endocrine Activities of cis and trans Isomers in a Series of Substituted Triphenylethylenes | Q59070106 | ||
| Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methanone, methanesulfonic acid salt | Q66944637 | ||
| Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata | Q67525218 | ||
| Nafoxidine--an antiestrogen for the treatment of breast cancer | Q67863330 | ||
| Effects of tamoxifen on cardiovascular risk factors in postmenopausal women | Q68060159 | ||
| Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse | Q68255846 | ||
| Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice | Q68773927 | ||
| Species-specific pharmacology of antiestrogens: role of metabolism | Q68958244 | ||
| Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model | Q69120520 | ||
| Effects of anti-estrogens on bone in castrated and intact female rats | Q69465128 | ||
| Tamoxifen and contralateral breast cancer | Q69867231 | ||
| Tamoxifen as risk factor for carcinoma of corpus uteri | Q69923105 | ||
| Tamoxifen and endometrial cancer | Q69925164 | ||
| Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy | Q70120469 | ||
| Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice | Q71218559 | ||
| Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor | Q71236005 | ||
| Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model | Q71500273 | ||
| Role of Estrogens in Ovulation: A Study Using the Estrogen-Antagonist, I.C.I. 46,474 | Q71554251 | ||
| Antagonism of estrogen action with a new benzothiophene derived antiestrogen | Q71670392 | ||
| New synthetic agent for the induction of ovulation: preliminary trials in women | Q71747708 | ||
| Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy | Q71786728 | ||
| Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018 | Q71791711 | ||
| Anti-implantation effect of 2,3-diphenylacrylophenones | Q71859586 | ||
| Mode of action of I.C.I. 46,474 in preventing implantation in rats | Q72332193 | ||
| Mammalian Antifertility Agents. III. 1-Aryl-2-phenyl-1,2,3,4-tetrahydro-1-naphthols, 1-Aryl-2-phenyl-3,4-dihydronaphthalenes, and Their Derivatives1 | Q72781055 | ||
| CLOMIPHENE CITRATE (NSC-35770) IN DISSEMINATED MAMMARY CARCINOMA | Q77174178 | ||
| A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol | Q78324064 | ||
| Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29 | Q78780712 | ||
| Cataracts in Patients Treated with Triparanol | Q78977700 | ||
| Induction of ovulation with MRL/41. Preliminary report | Q79400527 | ||
| Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial | Q79803594 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3-12 | |
| P577 | publication date | 2014-06-17 | |
| P1433 | published in | Steroids | Q15716675 |
| P1476 | title | The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators | |
| P478 | volume | 90 |
| Q42666503 | A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β. |
| Q85208754 | Identification of black market products and potential doping agents in Germany 2010-2013 |
| Q38745892 | Proliferative Properties of 17β-aminoestrogens in MCF-7 Human Breast Cancer Cells. |
| Q26783076 | Roles for miRNAs in endocrine resistance in breast cancer |
Search more.